	US 11,746,136 B2
	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
Steven David Goodman, Hilliard, OH (US); and Lauren O. Bakaletz, Hilliard, OH (US)
Assigned to Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
Appl. No. 16/492,582
Filed by Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
PCT Filed Mar. 14, 2018, PCT No. PCT/US2018/022508 § 371(c)(1), (2) Date Sep. 9, 2019, PCT Pub. No. WO2018/170178, PCT Pub. Date Sep. 20, 2018.
Claims priority of provisional application 62/471,834, filed on Mar. 15, 2017.
Prior Publication US 2021/0139551 A1, May 13, 2021
Int. Cl. C07K 14/52 (2006.01); A61P 31/04 (2006.01); A01N 63/50 (2020.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01)

CPC C07K 14/52 (2013.01) [A01N 63/50 (2020.01); A61K 38/19 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01)]

6 Claims

1. A method for inhibiting, competing or titrating the binding of a deoxyribonucleic acid B II (DNABII) polypeptide to a microbial DNA in a biofilm, comprising contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising C45S thereby inhibiting, competing or titrating the binding of the DNABII polypeptide to the microbial DNA.